Receiving an Alzheimer’s disease diagnosis can feel overwhelming, but advances in research continue to provide new treatment options that may help eligible patients manage the disease earlier than ever before.
Recently, the U.S. Food and Drug Administration (FDA) approved LEQEMBI IQLIK® (lecanemab-irmb) subcutaneous injection as a starting treatment option for certain patients with early Alzheimer’s disease. This approval represents an important milestone because it allows eligible patients to begin therapy with a once-weekly subcutaneous injection that can be administered at home, either by the patient or with the assistance of a caregiver.
While this development is exciting, it’s important to understand who may benefit from this treatment, how it works, and why evaluation by a neurologist remains essential.
What Is LEQEMBI?
LEQEMBI (lecanemab-irmb) is a disease-modifying therapy designed to target amyloid-beta plaques in the brain.
Amyloid plaques are one of the hallmark changes associated with Alzheimer’s disease. Rather than simply treating symptoms, LEQEMBI works by reducing these abnormal protein deposits, with the goal of slowing disease progression in appropriately selected patients.
Unlike medications that temporarily improve memory or thinking, disease-modifying therapies aim to influence the underlying biology of Alzheimer’s disease.
What’s New About This FDA Approval?
Previously, patients receiving LEQEMBI typically began treatment through intravenous (IV) infusions.
The newly approved LEQEMBI IQLIK® allows eligible patients to begin treatment with a once-weekly subcutaneous injection that can be administered at home after appropriate medical evaluation and instruction.
According to the FDA approval announcement, this is the first anti-amyloid therapy approved in the United States that offers both initiation and maintenance dosing through an at-home subcutaneous injection for eligible patients. The companies plan to make the new formulation available in the U.S. beginning in late August 2026.
Potential benefits include:
- Greater convenience for patients and caregivers
- Reduced need for frequent infusion center visits
- Improved access for individuals with transportation challenges
- Increased flexibility throughout treatment
Who Is Eligible for This Treatment?
LEQEMBI is not intended for every person diagnosed with Alzheimer’s disease.
Current FDA labeling indicates that treatment should be initiated in patients with:
- Mild Cognitive Impairment (MCI) due to Alzheimer’s disease, or
- Mild Alzheimer’s dementia,
and only after confirmation that amyloid pathology is present.
Before starting treatment, patients typically undergo:
- A comprehensive neurological evaluation
- Cognitive testing
- Brain imaging
- Biomarker testing to confirm amyloid pathology
- Additional safety assessments to determine whether the therapy is appropriate
How Effective Is LEQEMBI?
Clinical studies have shown that LEQEMBI can slow cognitive decline in selected patients with early Alzheimer’s disease.
It’s important to understand that this medication is not a cure and does not reverse Alzheimer’s disease. Instead, its purpose is to slow progression for eligible individuals by addressing one of the biological processes involved in the disease.
Researchers continue to study long-term outcomes as additional evidence becomes available.
Are There Risks?
Like all prescription medications, LEQEMBI carries potential risks.
Some patients may experience side effects, including:
- Injection site reactions
- Headache
- Flu-like symptoms
Additionally, anti-amyloid therapies can be associated with a condition known as Amyloid Related Imaging Abnormalities (ARIA), which may involve swelling or small areas of bleeding in the brain. Because of this risk, neurologists carefully evaluate patients before treatment and monitor them with periodic MRI scans during therapy.
This is why treatment should only be managed by healthcare professionals experienced in caring for patients with Alzheimer’s disease.
Why Early Diagnosis Matters
One of the most important messages from this FDA approval is that early diagnosis matters.
Many disease-modifying therapies are intended for patients in the earliest stages of Alzheimer’s disease. Waiting until symptoms become more advanced may limit treatment options.
Early evaluation can help determine:
- Whether memory changes are related to Alzheimer’s disease
- Whether another neurological condition is responsible
- Whether new treatment options may be appropriate
- What strategies can help maintain quality of life
